Just six days into 2015, the US biotechnology industry already is halfway to the $1.1bn in venture capital raised during the first three months of 2014, including a $48m Series B round for Global Blood Therapeutics (GBT), a $65m Series D for Seres Health and a $20m Series C for CytomX.
The three 6 January VC funding announcements were preceded by $76.4m in new financings for Aduro Biotech, Symic Biomedical and...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
